Please login to the form below

Not currently logged in
Email:
Password:

Millennium expands Velcade tests

Millennium Pharmaceuticals begins tests to evaluate its blood cancer drug Velcade in combination with other drugs

Millennium Pharmaceuticals has begun tests to evaluate its blood cancer drug Velcade (bortezomib) in combination with other drugs.

Velcade, which Millennium is developing with Johnson & Johnson Pharmaceutical Research and Development (J&JPRD), can be prescribed to patients with multiple myeloma who have received at least one prior therapy.

The phase II trial will evaluate the efficacy of combining Velcade for injection with lenalidomide, dexamethasone and cyclophosphamide in the front-line multiple myeloma setting.

In a press statement, Millennium's CMO Nancy Simonian, said: "The objective of this trial is to evolve the treatment of multiple myeloma by combining these highly active therapies to induce early complete remission and improve long term survival."

16th August 2007

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Bedrock Healthcare Communications

Bedrock Healthcare Communications is a privately owned, award winning communications agency that creates and delivers highly effective, insight driven medical...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics